PDS Biotechnology Corp Net Income
| PDSB Stock | USD 0.70 0.02 2.94% |
As of the 17th of February 2026, PDS Biotechnology holds the Market Risk Adjusted Performance of (0.17), coefficient of variation of (1,486), and Risk Adjusted Performance of (0.05). Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of PDS Biotechnology, as well as the relationship between them.
PDS Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing PDS Biotechnology's valuation are provided below:We have found one hundred twenty available trending fundamental ratios for PDS Biotechnology Corp, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of PDS Biotechnology Corp recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself next year. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -33.8 M | -35.5 M | |
| Net Loss | -36.8 M | -34.9 M | |
| Net Loss | -33.8 M | -35.5 M | |
| Net Loss | (0.93) | (0.98) | |
| Net Income Per E B T | 1.12 | 2.00 |
PDS | Net Income | Build AI portfolio with PDS Stock |
Analyzing PDS Biotechnology's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing PDS Biotechnology's current valuation and future prospects.
Latest PDS Biotechnology's Net Income Growth Pattern
Below is the plot of the Net Income of PDS Biotechnology Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in PDS Biotechnology Corp financial statement analysis. It represents the amount of money remaining after all of PDS Biotechnology Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is PDS Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PDS Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (37.61 M) | 10 Years Trend |
|
Net Income |
| Timeline |
PDS Net Income Regression Statistics
| Arithmetic Mean | (24,786,356) | |
| Coefficient Of Variation | (65.85) | |
| Mean Deviation | 14,864,611 | |
| Median | (28,079,000) | |
| Standard Deviation | 16,322,981 | |
| Sample Variance | 266.4T | |
| Range | 46.2M | |
| R-Value | (0.62) | |
| Mean Square Error | 174.9T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (2,004,682) | |
| Total Sum of Squares | 4263T |
PDS Net Income History
Other Fundumenentals of PDS Biotechnology Corp
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
PDS Biotechnology Net Income component correlations
PDS Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for PDS Biotechnology is extremely important. It helps to project a fair market value of PDS Stock properly, considering its historical fundamentals such as Net Income. Since PDS Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PDS Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PDS Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. Anticipated expansion of PDS directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PDS Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate PDS Biotechnology Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating PDS Biotechnology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause PDS Biotechnology's market price to deviate significantly from intrinsic value.
It's important to distinguish between PDS Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PDS Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, PDS Biotechnology's market price signifies the transaction level at which participants voluntarily complete trades.
PDS Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PDS Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PDS Biotechnology.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in PDS Biotechnology on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding PDS Biotechnology Corp or generate 0.0% return on investment in PDS Biotechnology over 90 days. PDS Biotechnology is related to or competes with Actinium Pharmaceuticals, Xilio Development, OnKure Therapeutics, Tempest Therapeutics, Kezar Life, Reviva Pharmaceuticals, and Annovis Bio. PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer ... More
PDS Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PDS Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PDS Biotechnology Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 27.78 | |||
| Value At Risk | (8.41) | |||
| Potential Upside | 8.08 |
PDS Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PDS Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PDS Biotechnology's standard deviation. In reality, there are many statistical measures that can use PDS Biotechnology historical prices to predict the future PDS Biotechnology's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.18) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PDS Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PDS Biotechnology February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 4.07 | |||
| Coefficient Of Variation | (1,486) | |||
| Standard Deviation | 5.3 | |||
| Variance | 28.07 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 27.78 | |||
| Value At Risk | (8.41) | |||
| Potential Upside | 8.08 | |||
| Skewness | 0.6145 | |||
| Kurtosis | 1.13 |
PDS Biotechnology Corp Backtested Returns
At this point, PDS Biotechnology is very risky. PDS Biotechnology Corp maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of standard deviation over the last 3 months. We have found twenty-three technical indicators for PDS Biotechnology Corp, which you can use to evaluate the volatility of the company. Please check PDS Biotechnology's Coefficient Of Variation of (1,486), risk adjusted performance of (0.05), and Market Risk Adjusted Performance of (0.17) to confirm if the risk estimate we provide is consistent with the expected return of 0.0029%. The company holds a Beta of 2.03, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PDS Biotechnology will likely underperform. PDS Biotechnology Corp currently holds a risk of 4.95%. Please check PDS Biotechnology Corp kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if PDS Biotechnology Corp will be following its historical price patterns.
Auto-correlation | -0.12 |
Insignificant reverse predictability
PDS Biotechnology Corp has insignificant reverse predictability. Overlapping area represents the amount of predictability between PDS Biotechnology time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PDS Biotechnology Corp price movement. The serial correlation of -0.12 indicates that less than 12.0% of current PDS Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
PDS Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, PDS Biotechnology Corp reported net income of (37.61 Million). This is 111.02% lower than that of the Biotechnology sector and 153.69% lower than that of the Health Care industry. The net income for all United States stocks is 106.59% higher than that of the company.
PDS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDS Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDS Biotechnology could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics of similar companies.PDS Biotechnology is currently under evaluation in net income category among its peers.
PDS Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in PDS Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of PDS Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PDS Biotechnology's value.| Shares | Commonwealth Equity Services Inc | 2025-06-30 | 90.7 K | Millennium Management Llc | 2025-06-30 | 81.4 K | Integrys Wealth Advisors Llc | 2025-06-30 | 78.5 K | Jane Street Group Llc | 2025-06-30 | 69.3 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 68.5 K | Tempus Wealth Planning, Llc | 2025-06-30 | 47.8 K | Virtu Financial Llc | 2025-06-30 | 32 K | Bank Of New York Mellon Corp | 2025-06-30 | 29.3 K | T. Rowe Price Associates, Inc. | 2025-06-30 | 24.3 K | Armistice Capital, Llc | 2025-06-30 | 2.2 M | Vanguard Group Inc | 2025-06-30 | 2 M |
PDS Fundamentals
| Return On Equity | -2.22 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 30.12 M | ||||
| Shares Outstanding | 54.72 M | ||||
| Shares Owned By Insiders | 2.69 % | ||||
| Shares Owned By Institutions | 10.48 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 4.06 X | ||||
| EBITDA | (33.75 M) | ||||
| Net Income | (37.61 M) | ||||
| Cash And Equivalents | 52.98 M | ||||
| Cash Per Share | 1.86 X | ||||
| Total Debt | 21.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (35.03 M) | ||||
| Short Ratio | 2.58 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 24 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 38.35 M | ||||
| Total Asset | 45.36 M | ||||
| Retained Earnings | (182.11 M) | ||||
| Working Capital | 27.97 M | ||||
| Current Asset | 39.11 M | ||||
| Current Liabilities | 4.54 M | ||||
| Net Asset | 45.36 M |
About PDS Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PDS Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PDS Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PDS Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. Anticipated expansion of PDS directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PDS Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate PDS Biotechnology Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating PDS Biotechnology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause PDS Biotechnology's market price to deviate significantly from intrinsic value.
It's important to distinguish between PDS Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PDS Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, PDS Biotechnology's market price signifies the transaction level at which participants voluntarily complete trades.